2348.HK HKSE
Dawnrays Pharmaceutical (Holdings) Limited
1W: +0.0%
1M: -2.5%
3M: -3.0%
YTD: -18.5%
1Y: -27.1%
3Y: -9.3%
5Y: -29.2%
HK$0.97 ($0.12)
-0.01 (-0.51%)
Weekly Expected Move ±2.0%
HK$1
HK$1
HK$1
HK$1
HK$1
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$1.1B
-7.9% ▼
5Y CAGR: +2.2%
Gross Profit
$578M
-10.0% ▼
5Y CAGR: +2.0%
Operating Income
$368M
+32.6% ▲
5Y CAGR: +4.8%
Net Income
$565M
+73.3% ▲
5Y CAGR: +17.2%
EPS (Diluted)
$0.38
+72.7% ▲
5Y CAGR: +18.9%
EBITDA
$280M
-43.8% ▼
5Y CAGR: -3.9%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $1.0B | $1.2B | $1.3B | $1.2B | $1.1B |
| YoY Growth | +7.8% | +13.8% | +9.7% | -9.9% | -7.9% |
| Cost of Revenue | $479M | $490M | $511M | $510M | $483M |
| Gross Profit | $546M | $675M | $767M | $642M | $578M |
| Gross Margin | 53.3% | 58.0% | 60.0% | 55.7% | 54.5% |
| R&D Expenses | $60M | $67M | $79M | $91M | $71M |
| SG&A Expenses | $164M | $226M | $265M | $260M | $254M |
| Operating Expenses | $224M | $293M | $344M | $199M | $210M |
| Operating Income | $320M | $381M | $422M | $277M | $368M |
| Operating Margin | 31.3% | 32.7% | 33.1% | 24.1% | 34.7% |
| Interest Expense | $5M | $641K | $371K | $989K | $4M |
| Income Before Tax | $331M | $439M | $438M | $414M | $637M |
| Tax Expense | $67M | $85M | $83M | $91M | $74M |
| Net Income | $268M | $358M | $358M | $326M | $565M |
| Net Margin | 26.2% | 30.7% | 28.0% | 28.3% | 53.3% |
| EPS (Diluted) | $0.17 | $0.24 | $0.24 | $0.22 | $0.38 |
| EBITDA | $396M | $434M | $505M | $499M | $280M |
| Shares Outstanding | 1.55B | 1.51B | 1.50B | 1.50B | 1.51B |